Dose and Administration Schedule Effect of Tiludronate on Joint Damage in the Model of Complete Freund Adjuvant Induced Monoarthritis in Rats

Thierry Bertaim, Eric Chapuy, François Caussade, Denis Ardid

ANS Biotech, Facultés de Médecine et Pharmacie, Clermont-Ferrand, France.
Ceva Santé Animale, R&D, Libourne, France.
Laboratoire de Pharmacologie Médicale, Facultés de Médecine et Pharmacie, Clermont-Ferrand, France.

DOI: 10.4236/ojra.2013.31004                

Abstract

The effects of dose and administration schedule of Tiludronate (TA) were assessed on joint lesions and hyperalgesia in a rat model of monoarthritis induced by injection of Complete Freund Adjuvant into the tibio tarsal joint of the hindpaw on day 0 (D0). Rats (n = 12/group) received subcutaneous injection of saline at D1, D4, D8 and D12; single dose (15 mg/kg; 60 mg/kg) at D1 or repeated doses (15 mg/kg) at D1, D4, D8 and D12 of TA; or daily injection of Meloxicam (1 mg/kg, from D1 to D12). Joint lesion severity, hindpaw volume and hyperalgesia were evaluated using radiography, plethysmometry and paw pressure, respectively. TA dose dependently reduced radiographic joint lesion (p < 0.001), including bone demineralisation and erosion, joint deformation and to a lesser extent, soft tissue and space articular narrowing. These results were supported by a significant limited increase of paw volume at the highest dose, independently of the administration schedule (60 mg/kg, 4 × 15 mg/kg) within D12-D28 (p < 0.01). In contrast, Meloxicam had no effect on radiographic joint lesion and significantly reduced paw volume only within D0-D12 (p < 0.01). Irrespective of dose and administration schedule, TA had a significant partial anti hyperalgesic effect (p < 0.05) within D0-D12 that was sustained until D28. In contrast, Meloxicam had a significant early anti hyperalgesic effect (p < 0.001) that was not sustained overtime. In conclusion, early TA administration showed a beneficial effect on joint lesion severity, with a partial anti hyperalgesic effect indicating that TA might be helpful for the management of arthritic pathologies with bone remodelling and osteolysis.

Keywords

Tiludronate; Arthritis; Bone Remodelling; Hyperalgesia

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	M. J. Rogers, “New Insights into the Molecular Mechanisms of Action of Biphosphonates,” Current Pharmaceutical Design, Vol. 9, No. 32, 2003, pp. 2643-2658. doi:10.2174/1381612033453640
[2]	J. P. Bonjour, P. Ammann, A. Barbier, J. Caverzasio and R. Rizzoli, “Tiludronate: Bone Pharmacology and Safety,” Bone, Vol. 17, No. 5, 1995, pp. 473S-477S. doi:10.1016/8756-3282(95)00344-9
[3]	G. Shu, K. Yamamoto and M. Nagashima, “Differences in Osteoclast Formation between Proximal and Distal Tibial Osteoporosis in Rats Adjuvant Arthritis: Inhibitory Effects of Biphosphonates on Osteoclasts,” Molecular Rheumatology, Vol. 16, No. 6, 2006, pp. 343-349. doi:10.1007/s10165-006-0515-1
[4]	C. Roux and M. Dougados, “Treatment of Patients with Paget’s Disease of Bone,” Drugs, Vol. 58, No. 5, 1999, pp. 823-830. doi:10.2165/00003495-199958050-00005
[5]	P. D. Delmas, “Treatment of Postmenopausal Osteoporosis,” Lancet, Vol. 359, No. 9322, pp. 2018-2026. doi:10.1016/S0140-6736(02)08827-X
[6]	R. G. Russell, Z. Xia, J. E. Dunford, U. Oppermann, A. Kwaasi, P. A. Hulley, K. L. Kavanagh, J. T. Triffitt, M. W. Lundy, R. J. Phipps, B. L. Barnett, F. P. Coxon, M. J. Rogers, N. B. Watts and F. H. Ebetino, “Bisphosphonates: an Update on Mechanisms of Action and How These Relate to Clinical Efficacy,” Annual New York Academic Sciences, Vol. 1117, No. 1, 2002, 2007, pp. 209-257.
[7]	C. O. Bingham, J. C. Buckland-Wright, P. Garnero, S. B. Cohen, S. M. Dougado, S. Adarni, “Risedronate Decreases Biochemical Markers of Cartilage Degradation but Does Not Decrease Symptoms or Slow Radiographic Progression in Patients with Medial Compartment Osteoarthritis of the Knee E Results of the Two-Year Multinational Knee Osteoarthritis Structural Arthritis Study,” Arthritis Rheumatology, Vol. 54, No. 11, 2006, pp. 3494-3507. doi:10.1002/art.22160
[8]	J. Martel-Pelletier, D. Lajeunesse and J. P. Pelletier, “Etiopathogenesis of Osteoarthritis,” In: W. J. Koopman and L. W. Moreland, Eds., A Textbook of Rheumatology, Lippincott, Williams & Wilkins Publishers, Baltimore, 2005, pp. 2199-2226.
[9]	S. Kwan Tat, D. Lajeunesse, J. P. Pelletier and J. Martel-Pelletier, “Targeting Subchondral Bone for Treating Osteoarthritis: What is the Evidence?” Best Practice Research Clinical Rheumatology, Vol. 24, No. 1, 2010, pp. 51-70. doi:10.1016/j.berh.2009.08.004
[10]	B.W. Strassle, L. Mark, L. Leventhal, M. J. Piesla, X. Jian Li, J. D. Kennedy and S. S. Glasson, “Inhibition of Osteoclasts Prevents Cartilage Loss and Pain in a Rat Model of Degenerative Joint Disease,” Osteoarthitis and Cartilage, Vol. 18, No. 10, 2010, pp. 1319-1328. doi:10.1016/j.joca.2010.06.007
[11]	C. Delguste, H. Amory, M. Doucet, C. Piccot-Crozollet, D. Thibaud, P. Garnero, J. Detilleux and O. M. Lepage, “Pharmacological Effects of Tiludronate in Horses after Long-Term Immobilization,” Bone, Vol. 41, No. 3, 2007, pp. 414-421. doi:10.1016/j.bone.2007.05.005
[12]	V. Coudry, D. Thibaud, B. Riccio, F. Audigi, D. Didierlaurent and J. M. Denoix, “Efficacy of Tiludronate in the Treatment of Horses with Signs of Pain Associated with Osteoarthritic Lesions of the Thoracolumbar Vertebral Column,” American Journal of Veterinary Research, Vol. 68, No. 3, 2007, pp. 329-337. doi:10.2460/ajvr.68.3.329
[13]	M. R. Gough, D. Thibaud and R. K. Smith, “Tiludronate Infusion in the Treatment of Bone Spavin: A Double Blind Placebo-Controlled Trial,” Equine Veterinary Journal, Vol. 42, No. 5, 2010, pp. 381-387. doi:10.1111/j.2042-3306.2010.00120.x
[14]	J. M. Denoix, D. Thibaud and B. Riccio, “Tiludronate as a New Therapeutic Agent in the Treatment of Navicular Disease: A Double-Blind Placebo-Controlled Clinical Trial,” Equine Veterinary Journal, Vol. 35, No. 4, 2003, pp. 407-413. doi:10.2746/042516403776014226
[15]	H. Harada, T. Nakayama, T. Nanaka and T. Katsumata, “Effects of Bisphosphonates on Joint Damage and Bone Loss in Rat Adjuvant-Induced Arthritis,” Inflammation Research, Vol. 53, No. 2, 2004, pp. 45-52. doi:10.1007/s00011-003-1214-4
[16]	H. Vermeirsch, R. Biermans, P. Salmon and T. Meert, “Evaluation of Pain Behavior and Bone Destruction in Two Arthritic Models in Guinea Pig and Rat,” Pharmacology Biochemistry and Behavior, Vol. 87, No. 3, 2007, pp. 349-359. doi:10.1016/j.pbb.2007.05.010
[17]	M. Nagae, T. Hiraga, H. Wakabayashi, L. Wang, K. Iwata and T. Yoneda, “Osteoclasts Play a Part in Pain Due to the Inflammation Adjacent to Bone,” Bone, Vol. 39, No. 5, 2006, pp. 1107-1115. doi:10.1016/j.bone.2006.04.033
[18]	M. Nagae, T. Hirage and T. Yoneda, “Acidic Microenvironment Created by Osteoclasts Causes Bone Pain Associated with Tumor Colonization,” Journal of Bone and Mineral Metabolism, Vol. 25, No. 2, 2007, pp. 99-104. doi:10.1007/s00774-006-0734-8
[19]	S. H. Butler, F. Godefroy, J. M. Besson and J. Weil-Fugazza, “A Limited Arthritic Model for Chronic Pain,” Pain, Vol. 48, No. 1, 1992, pp. 73-81. doi:10.1016/0304-3959(92)90133-V
[20]	O. Barou, M. H. Lafage-Proust, C. Martel, T. Thomas, F. Tirode, N. Laroche, A. Barbier, C. Alexandre and L. Vico, “Biphosphonate Effects in Rat Unloaded Hindlimb Bone Loss Model: Three-Dimensional Microcomputed Tomographic, Histomorphometric, And Densitometric Analyses,” Journal of Pharmacology and Experimental Therapy, Vol. 291, No. 1, 1999, pp. 321-328.
[21]	L. O. Randall and J. J. Selitto, “A Method for Measurement of Analgesic Activity on Inflamed Tissue,” Archives Intrenationales de Pharmacodynamie et de Thérapie Vol. 111, No. 4, 1957, pp. 409-419.
[22]	A. Bendele, J. Mc Comb, T. Gould, T. Mc Abee, G. Sennello and E. Chlipalla, “Animal Model of Arthritis: Relevance to Human Disease,” Toxicology Pathology, Vol. 27, No. 1, 1999, pp. 134-142. doi:10.1177/019262339902700125
[23]	C. Stein, M. J. Millan and A. Nerz, “Unilateral Inflammation of the Hindpaw in Rats as a Model of Prolonged Noxious Stimulation: Alterations in Behavior and Nociceptive Thresholds,” Pharmacology Biochemistry and Behavior, Vol. 31, No. 2, 1988, pp. 445-451. doi:10.1016/0091-3057(88)90372-3
[24]	H. Murakami, T. Nakamura, H. Tsurukami, M. Abe, A. Barbier and K. Suzuki, “Effects of Tiludronate on Bone Mass, Structure and Turnover at the Epiphyseal, the Primary and the Secondary Spongiosae in the Proximal Tibia of Growing Rats after Sciatic Neurectomy,” Journal of Bone and Mineral Research, Vol. 9, No. 9, 1994, pp. 1355-1364. doi:10.1002/jbmr.5650090906
[25]	Y. H. Koh, S. H. Hong, H. S. Kang, C. Y. Chung, K. H. Koo, H. W. Chung, J. H. Cha, K. R. Son, “The Effects of Bone Turnover Rate on Subchondral Trabecular Bone Structure and Cartilage Damage in the Osteoarthritic Rat Model,” Rheumatology and Internal Medicine, Vol. 30, No. 9, 2010, pp. 1165-1171.
[26]	J. P. Barbier, P. Bonjour, M. C. Geusens and F. L. De Vernejoul, “Tiludronate: A Biphosphonate with a Positive Effect on Bone Quality in Experimental Models,” Journal of Bone and Mineral Research, Vol. 6, Suppl. 1, 1991, p. S531.
[27]	K. D. Peterson and T. J. Keefe, “Effects of Meloxicam on Severity of Lameness and Other Clinical Signs of Osteoarthritis in Dogs,” Journal of American Veterinary Medicine Association, Vol. 225, No. 7, 2004, pp. 1056-1060. doi:10.2460/javma.2004.225.1056
[28]	P. Amman, R. Rizzoli, J. Caverzasio, T. Shigematsu, D. Slosman and J. P. Bonjour, “Effects of the Bisphosphonate Tiludronate on Bone Resorption, Calcium Balance, and Bone Mineral Density,” Journal of Bone and Mineral Research,, Vol. 8, No. 12, 1993, pp. 1491-1498.
[29]	T. Hayami, M. Pickarski, G. A. Wesolowski, J. McLane, A. Bone, J. Destefano, G. A. Rodan and T. Le Duong, “The Role of Subchondral Bone Remodelling in Osteoarthritis: Reduction of Cartilage Degeneration and Prevention of Osteophyte Formation by Alendronate in the Rat Anterior Cruciate Ligament Transection Model,” Arthritis Rheumatology, Vol. 50, No. 4, 2004, pp. 1193-1206. doi:10.1002/art.20124
[30]	P. David, H. Nguyen, A. Barbier and R. Baron, “The Bisphosphonate Tiludronate Is a Potent Inhibitor of the Osteoclast Vacuolar H+-ATPase,” Journal of Bone and Mineral Research, Vol. 11, No. 10, 1996, pp. 1498-507. doi:10.1002/jbmr.5650111017
[31]	H. Murakami, N. Takahashi, S. Tanaka, I. Nakamura, N. Udagawa, S. Nakajo, K. Nakaya, M. Abe, Y. Yuda, F. Konno, A. Barbier and T. Suda, “Tiludronate Inhibits Protein Tyrosine Phosphatase Activity in Osteoclasts,” Bone, Vol. 20, No. 5, 1997, pp. 399-404. doi:10.1016/S8756-3282(97)00025-2
[32]	K. Suzuki, S. Takeyama, Y. Sakai, S. Yamada and H. Shinoda, “Current Topics in Parmacological Research on Bone Metabolism: Inhibitory Effects of Biphosphonates on the Differentiation and Activity of Osteoclasts,” Journal Pharmacology Sciences, Vol. 100, No. 3, 2006, pp. 189-194. doi:10.1254/jphs.FMJ05004X2
[33]	D. A. Walsh and V. Chapman, “Bisphosphonates for Osteoarthritis,” Arthritis Research Therapy, Vol. 13, No. 5, 2011, pp. 128-134. doi:10.1186/ar3448
[34]	B. Le Goff, E. Soltner, C. Charrier, Y. Maugars, F. Rédini, D. Heymann and J. M. Berthelot, “A Combination of Methotrexate and Zoledronic Acid Prevents Bone Erosions and Systemic Bone Mass Loss in Collagen Induced Arthritis,” Arthritis Research Therapy, Vol. 11, No. 6, 2009, pp. R185-R191. doi:10.1186/ar2877
[35]	M. D. Jones, C. Tran, G. Li, W. P. Maksymowych, R. Zernicke, M. Doschak, “In vivo Microfocal Computed Tomography and Micro-Magnetic Resonance Imaging Evaluation of Antiresorptive and Anti-Inflammatory Drugs As Preventive Treatments of Osteoarthritis in the Rat,” Arthritis Rheumatology, Vol. 62, No. 9, 2010, pp. 2726-2735. doi:10.1002/art.27595